Off the shelf. Capivasertib, sold under the brand name Truqap, is an expensive cancer drug. Its monthly cost can range from $5,141 to over $22,000 for a specific dosage, according to a Medical News Today article. The combination of capivasertib with fulvestrant can also be costly, with an estimated incremental cost of $305,148 compared to fulvestrant alone. Here's a more detailed breakdown: Monthly Cost: A study indicated a monthly cost of capivasertib at $5,141 when combined with fulvestrant. Overall Cost: The cost of capivasertib plus fulvestrant can reach $488,915. Cost-Effectiveness: Some analyses suggest that capivasertib, when added to fulvestrant, may not be cost-effective compared to fulvestrant alone, particularly within certain cost-effectiveness thresholds. Price Reduction Needed: To achieve cost-effectiveness in some scenarios, significant price reductions are needed, potentially by as much as 85%. Specific Dosage Example: One source mentions a price of $22,641.14 for 64 tablets of 200mg Truqap. In essence, capivasertib is a high-priced medication, and its cost-effectiveness can be a concern, particularly when compared to other treatment options.
Learn More